New drug shows promise in calming inflammation for kidney patients
NCT ID NCT04626505
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested a drug called ziltivekimab in 36 adults with advanced chronic kidney disease and high inflammation. The goal was to see if it could safely reduce inflammation and lower heart disease risks. Participants received either a low dose, a high dose, or a placebo injection every 4 weeks for 3 doses. The study measured changes in a key inflammation marker (hs-CRP) and tracked side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ehime Medical Center
Ehime, 791-0281, Japan
Conditions
Explore the condition pages connected to this study.